Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3214996 and Abemaciclib in Recurrent Glioblastoma
NCT04391595Phase 1Completed
- Sponsor
- Ivy Brain Tumor Center
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temuterkib in glioblastoma (GBM), sponsored by Ivy Brain Tumor Center. Primary endpoints: Pharmacokinetic analysis of tumor tissue at 8 hours, Pharmacokinetic analysis of cerebrospinal fluid (CSF) at 8 hours and 2 more. Started Jul 2020; status: completed.
02
Drugs
temuterkib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04391595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391595.